IMATINIB AND STATINS
Imatinib increased the maximum serum levels of simvastatin 2-fold and the AUC 3.5-fold in one study.
These rises increase the risk of simvastatin toxicity (most notably myopathy and rhabdomyolysis), for which reason the simvastatin dosage should be reduced appropriately. Patients should be counselled regarding myopathy (e.g. report any unexplained muscle pain, tenderness or weakness).
These rises increase the risk of simvastatin toxicity (most notably myopathy and rhabdomyolysis), for which reason the simvastatin dosage should be reduced appropriately. Patients should be counselled regarding myopathy (e.g. report any unexplained muscle pain, tenderness or weakness).